category,datetime,headline,id,image,related,source,summary,url
company,1769255521,Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade),138246284,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156325176/image_2156325176.jpg?io=getty-c-w1536,BMY,SeekingAlpha,"Bristol Myers Squibb (BMY) is up ~27% in 3 months; learn why itâs now a Hold, key Eliquis replacement risks, and dividend outlookâread now.",https://finnhub.io/api/news?id=d07a42e23ccc3568ad77753e17cc9ff8ef106c09521633c14ff2e8193106858b
company,1769220864,Camzyos Trial Win and Microsoft AI Lung Program Might Change The Case For Investing In BMY,138231122,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BMY,Yahoo,"In January 2026, Bristol-Myers Squibb announced positive Phase 3 SCOUT-HCM results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy and unveiled an AI-focused collaboration with Microsoft to enhance early lung cancer detection across U.S. healthcare systems, including underserved communities. Together, these developments highlight how Bristol-Myers Squibb is pairing a maturing cardiovascular pipeline asset with digital oncology initiatives that could refine...",https://finnhub.io/api/news?id=32edbff4337ae7c7d74c6c8fa2ed91e4a3eeed900c5bd00e6b05fdbf54b40985
